Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients

Hasper, M. F.

doi:10.1001/archderm.119.10.812

Cited by 22 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in contrast to what has been suggested by other clinicians, that the dose be gradually decreased until treatment can be discontinued altogether. 33 The induction of long-term remission by thalidomide has not been reported, and this has been our experience as well. This suggests that a maintenance dose is necessary for long-term control of disease.…”

mentioning

confidence: 63%

“…Another study involving 11 patients reported that a maintenance dose of 25 to 50 mg every night or every other night was necessary to prevent relapse. 33 Other studies were also published confirming the effectiveness of thalidomide, 100 to 400 mg/d, in the cutaneous treatment of various forms of lupus erythematosus (LE). [34][35][36][37] The reported adverse effects in these studies included paresthesia, drowsiness, abdominal disturbances, dry mouth, urticaria, rash, mood changes, circulatory changes, amenorrhea, and edema.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

American Experience With Low-Dose Thalidomide Therapy for Severe Cutaneous Lupus Erythematosus

Duong¹,

Spigel²,

Moxley³

et al. 1999

Arch Dermatol

View full text Add to dashboard Cite

mentioning

confidence: 63%

Section: Discussionmentioning

confidence: 99%

American Experience With Low-Dose Thalidomide Therapy for Severe Cutaneous Lupus Erythematosus

Duong¹,

Spigel²,

Moxley³

et al. 1999

Arch Dermatol

View full text Add to dashboard Cite

“…Thereafter, in literature, more than 200 patients with DLE have been treated with thalidomide, obtaining 90% of improvement. However, 70% of patients had recurrence of the lesions after stopping treatment [14][15][16][17][18][19][20] . with good results 21,22 .…”

Section: And and M M M M Methods Ethods Ethods Ethods Ethodsmentioning

confidence: 99%

Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus

Sato¹,

Assis²,

Lourenzi³

et al. 1998

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

SUMMARY -Were selected 18 SLE patients (ACR criteria) with active cutaneous patients (ACR criteria) with active cutaneous patients (ACR criteria) with active cutaneous patients (ACR criteria) with active cutaneous patients (ACR criteria) with active cutaneous lesions not responsive to chloroquine, photolesions not responsive to chloroquine, photolesions not responsive to chloroquine, photolesions not responsive to chloroquine, photolesions not responsive to chloroquine, photoprotectors and low doses prednisone and who protectors and low doses prednisone and who protectors and low doses prednisone and who protectors and low doses prednisone and who protectors and low doses prednisone and who presented good response to thalidomide but represented good response to thalidomide but represented good response to thalidomide but represented good response to thalidomide but represented good response to thalidomide but relapsed after withdrawal of the drug. All female lapsed after withdrawal of the drug. All female lapsed after withdrawal of the drug. All female lapsed after withdrawal of the drug. All female lapsed after withdrawal of the drug. All female patients had no risk of pregnancy. Thalidomide patients had no risk of pregnancy. Thalidomide patients had no risk of pregnancy. Thalidomide patients had no risk of pregnancy. Thalidomide patients had no risk of pregnancy. Thalidomide was reintroduced and maintained at low dose was reintroduced and maintained at low dose was reintroduced and maintained at low dose was reintroduced and maintained at low dose was reintroduced and maintained at low dose (25-100mg/day) for a minimum of 6 months.

show abstract

“…Several years later it was discovered [23] that this compound was capable of rapidly alleviating the manifestations of type II lepra reactions; subsequently, the use of thalidomide has been empirically extended to a variety of dermatoses. More recently, this drug was shown to be effective in the management of lupus erythematosus [24,25], prurigo nodularis [26,27], severe aphthosis [28], Behçet's disease [29], adult Langerhans cell histiocytosis [30] and Jessner's lymphocytic infiltration [31].…”

Section: Discussionmentioning

confidence: 99%

Treatment of Porphyria cutanea tarda with Oral Thalidomide

Monastirli

Georgiou²,

Bolsen³

et al. 1999

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Eight male patients with overt clinical and biochemical features of porphyria cutanea tarda (PCT) were orally treated with 300 mg/day thalidomide for 1 week and with 200 mg/day for 3 more weeks. Already after the first week of treatment no new vesicles and/or bullae could be observed. Spontaneous blisters completely disappeared, increased skin fragility subsided and skin hyperpigmentation receded about 2 months after completion of therapy, whereas hypertrichosis persisted. There was a rapid decrease in the urinary total porphyrin excretion which reached normal levels in all patients by the end of the fourth week of therapy, whereas the posttreament chromatographic pattern of urinary porphyrins revealed a slight reduction of higher carboxylated porphyrin metabolites and an increase in the amount of the excreted coproporphyrin, as compared to the pretreatment period. Somnolence, intermittent constipation and dry mouth occurred in all patients, 2 patients additionally experienced dizziness. No evidence of peripheral neuropathy could be detected and laboratory investigations revealed no abnormalities, as compared to the pretreatment period. During the 16- to 28-month follow-up of the patients, no clinical or biochemical relapse was observed. In view of the encouraging results of the present investigation, further studies are now warranted in order to definitely answer the question whether oral thalidomide may be regarded as an effective alternative approach to the treatment of PCT.

show abstract

Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients

Cited by 22 publications

References 0 publications

American Experience With Low-Dose Thalidomide Therapy for Severe Cutaneous Lupus Erythematosus

American Experience With Low-Dose Thalidomide Therapy for Severe Cutaneous Lupus Erythematosus

Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus

Treatment of Porphyria cutanea tarda with Oral Thalidomide

Contact Info

Product

Resources

About